You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 康希諾生物-B漲4% 旗下重組型新型冠狀病毒疫苗Convidecia與Aerogen合作
格隆匯 12-14 13:49
格隆匯12月14日丨康希諾生物-B(6185.HK)現漲4.81%,報161.2港元,總市值399億港元。近日,Aerogen®(愛爾蘭戈爾韋)和康希諾生物宣佈,雙方就康希諾生物旗下全球首款吸入給藥新型冠狀病毒疫苗Convidecia™採用Aerogen專有振動式網孔氣霧劑給藥技術實現吸入給藥達成開發和商業供貨合作伙伴關係。康希諾生物開展的3期臨牀試驗中期結果顯示,Convidecia™單劑接種14天后,預防重症疾病的有效性為95.47% 1。另外,據央廣網,12月11日,在2021年大灣區科學論壇上,鍾南山院士展示重組新冠疫苗序貫加強後抗體水平變化數據,介紹接種重組疫苗加強劑的人羣顯著高於接種滅活疫苗的人羣;而在另一組試驗中,接種兩種滅活疫苗3-6個月後用康希諾疫苗加強,抗體會升高約200倍。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account